Drug Trial Radar · NCT07610369
The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Jul 10, 2026
Primary completion
Jul 2030
Study completion Jul 2030
Sponsor
- Lead sponsor
- Yale UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Michael J. Fox Foundation for Parkinson's Research
- First posted
- May 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.
Conditions
- Depression
- Parkinson's Disease (PD)
Interventions
Psilocybin (drug)Drug
Single dose of psilocybin ranging from low ("microdose") to high delivered orally with psychological support and monitoring
Psilocybin (drug)Drug
Single dose of psilocybin ranging from low ("microdose") to high delivered orally with psychological support and monitoring
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in depression as measured by the Montgomery-Asberg Depression Rating Scale (MADRS)Time frame: Baseline to 30 days after first drug dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Yale University
New Haven, Connecticut · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.